Patient with dizziness
Conditions
Interventions
Oral administration of protease-digested lyophilized powder of bee larvae (720 mg/day, 12weeks)
Oral administration of placebo (everyday, 12weeks)
Sponsors
Kawagoe Otology Institute
Research Center for Immunological Analysis. Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: [1] Subjects with dizziness who have not improved the symptoms with at least 4 weeks drug treatment.
Exclusion criteria
Exclusion criteria: [1] Individuals with acute vertigo (meniere's syndrome, benign paroxysmal positional vertigo, vestibular neuritis and so on) [2] Individuals with dizziness and vertigo caused by severe desease (cerebral infarction, intracranial hemorrhage, brain tumor and so on). [3] Individuals who have a severe allergy or asthma. [4] Heavy smoker or alcoholism. [5] Individuals whose dietary habit is excessively irregular. [6] Individuals who usually take bee larvae. [7] Individuals who have an infection needed systemic therapy. [8] Individuals who are considered that participation for this trial is difficult because of psychiatric symptoms or psychosis. [9] Individuals who have a kidney disease. [10] Individuals judged inappropriate for participating the study by the principal
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dizziness Handicap Inventory (DHI) (at a few weeks and 1 day before the intervention, and after 4, 8, 12, 16 weeks of daily intake.) | — |
Secondary
| Measure | Time frame |
|---|---|
| Frenzel eye movement measurement, stabilometry, the measurement with autonomic nervous system (at 1 day before the intervention, and after 4, 8, 12, 16 weeks of daily intake.) | — |
Countries
Japan
Contacts
Public ContactEmi Ogawa
Kawagoe Otology Institute Department of Otolaryngology
Outcome results
None listed